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To assess whether or not liver transplantation and subsequent immunosuppression with 
cyclosporine and prednisone affect ulcerative colitis symptomatology, we surveyed by 
questionnaire all 23 surviving patients with pretransplant colonoscopy-documented ulcer-
ative colitis who were transplanted for primary sclerosing cholangitis between June 1982 
and September 1985. At follow-up [89.8 ± 7.6 weeks (mean ± SEMj, all six patients who had 
had asymptomatic colonoscopy-documented ulcerative colitis reported continued ulcer-
ative colitis quiescence. Among the 17 patients who had had symptomatic colonoscopy-
documented ulcerative colitis at time of liver transplantation, 88.2% reported improvement 
in overall ulcerative colitis severity (P < 0.001), with significant improvement in the 
frequency of bowel movements reported by 100%. in crampy abdominal pain by 87.5%. in 
bowel urgency by 75%, in the occurrence ofpus or mucus in stool by 87.5%. in the incidence 
E~f ulcerative colitis flares by 81.8%, and in the number of days unable to function normally 
due to ulcerative colitis symptoms by 78.6% (all at least P < 0.01). These data demonstrate 
that ulcerative colitis symptom severity significantly improves following liver transplanta-
tion with immunosuppression with cyclosporine and prednisone. 
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Primary sclerosing cholangitis is a chronic chole-
static liver disease of unknown etiology that is 
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found in association with inflammatory bowel dis-
ease, particularly ulcerative colitis (1-8). Liver 
transplantation has been used to treat individuals 
with advanced primary sclerosing cholangitis only 
recently (9-13). 
This work was supported in part by NIDDK grant DK32556 
and by N IAAA grant AA0660 I. 
Address for reprint requests: Judith S. Gavaler, Ph.D., 572 
Scaife Hall, University of Pittsburgh School of Medicine, Pitts-
burgh, Pennsylvania 15261. 
Digestive Diseases and Sciences, Vol. 36, No.3 (March J99l) 
Whether or not primary sclerosing cholangitis 
recurs following liver transplantation and what the 
effect of the persistent presence of inflammatory 
bowel disease might have upon the clinical course 
and quality of life of patients receiving a liver 
transplant for advanced primary sclerosing cholan-
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gitis are unknown. Immunological factors are 
thought to be important in the pathogenesis of both 
sclerosing cholangitis and the underlying inflamma-
tory bowel disease (14-19). The present study was 
performed in a case series to evaluate ulcerative 
colitis symptomatology as assessed by patient-
completed questionnaires following liver transplan-
tation for end-stage liver disease. 
MATERIALS AND METHODS 
Between June 1982 and September 1985. a total of 35 
patients with colonoscopy- and biopsy-documented ul-
cerative colitis underwent orthotopic liver transplantation 
(OLTx) at the University of Pittsburgh. The indication for 
OL Tx was primary sclerosing cholangitis in 34 and con-
genital hepatic fibrosis in one. All patients were evaluated 
as potential liver recipients using the liver transplant 
protocol, which includes a full colonoscopy, in use at the 
institution. All the patients had an intact colon at time of 
transplant. Of these 35 patients, 12 died within 139 ± 55 
days (mean ± SEM) of surgery. 
The surviving 23 patients were sent a detailed question-
naire to assess their perception of their ability to function 
in usual activities, the status and severity of ulcerative 
colitis symptoms, medication usage, and occurrence of 
and treatment for ulcerative colitis flares (see Appendix). 
The response rate was 100%; in addition, follow-up phone 
calls were made to clarify ambiguous responses and to 
obtain missing information. Subjects were asked to clas-
sify the ulcerative colitis symptoms and severity, during 
the year prior to transplant and during the three month 
period prior to the time at which the questionnaire was 
completed, by indicating which of several categories 
provided best described a given symptom. 
The data were analyzed using the McNemar test of 
symmetry to evaluate changes in the proportion of pa-
tients in ulcerative colitis symptom severity categories, 
comparing the year prior to OLTx and the follow-up time 
point, which was at a different postoperative time point 
for each patient. Because of the relatively small number 
of patients who had had symptomatic ulcerative colitis 
prior to transplantation (N = 17), frequency categories 
for crampy abdominal pain, rectal pain, bowel urgency, 
rectal bleeding, and the presence of pus or mucus in the 
stool were combined as follows: frequency of symptoms 
more than or equal to several times a week was classified 
as high frequency, while the occurrence of symptoms 
several times a month or less was classified as low 
frequency. The binomial test was used to examine pro-
portions of patients who either improved or did not 
improve with respect to symptoms or functional status. 
Continuous data are reported as the mean ± SEM. Differ-
ences at the P < 0.05 level were considered to be 
statistically significant. 
RESULTS 
Quiescent Group. Six (26%) of the 23 patients had 
quiescent ulcerative colitis prior to liver transplan-
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tation and had not required treatment for their 
ulcerative colitis. Colonoscopy with multiple co-
lonic biopsies documented pan colitis to be present 
in all. The indication for OLTx in these six patients 
was primary sclerosing cholangitis. This clinically 
quiescent ulcerative colitis subgroup of four males 
and two females was 34.7 ± 6.2 years of age at time 
of OLTx, and the duration of their follow-up post 
OLTx was 109.9 ± 5.9 weeks (range: 104-136 
weeks). The daily immunosuppressive regimen in 
this group was 400.0 ± 44.7 mg of cyclosporine and 
10.8 ± 0.5 mg of prednisone. At time of follow-up, 
five patients (83.3%) were working full-time and one 
was not working but able to care for herself at 
home. All six patients reported themselves to be 
free of ulcerative colitis symptoms following trans-
plantation. 
Symptomatic Group. Seventeen patients, 11 
males and six females, had had symptomatic ulcer-
ative colitis prior to transplantation. Seven of these 
patients (40%) had mild clinical ulcerative colitis, 
eight had moderate colitis (47%), and two (13%) had 
severe clinical colitis. The duration of ulcerative 
colitis prior to OLTx was 15.4 ± 1.9 years. (The 
initial onset had been mild in 29.4%, moderate in 
47.1%, and severe in 23.5%). The course of the 
ulcerative colitis had been continuous in 35.3% and 
intermittent in 64.7%. Among the 11 patients with 
an intermittent course, the intervening attacks had 
been severe in two, moderate in seven, and mild in 
two. Prior to transplant, 66.7% of these patients had 
been treated for their ulcerative colitis with sul-
fasalazine, 46.7% with steroid enemas, 40.0% with 
Lomotil, 26.7% with prednisone, and 18.8% with 
azathioprine. Colonoscopy performed during eval-
uation for liver transplantation demonstrated pan-
colitis to be present in all 17 patients. Histologi-
cally, prior to transplantation, 80% of the subjects 
had minimal disease based upon a histologic exam-
ination of multiple colonic biopsies obtained at the 
time of the preoperative colonoscopy. Ten percent 
of the subjects had moderate and 10% had severe 
colitis histologically. 
At time of transplant, the mean range was 39.8 ± 
1.6 years; the indication for OLTx was primary 
sclerosing cholangitis in 16 and congenital hepatic 
fibrosis in one. In this subgroup of 17 patients with 
symptomatic ulcerative colitis prior to OLTx, the 
duration offollow-up was 82.7 ± 9.6 weeks. (range: 
31-175 weeks). At time of follow-up, the daily 
immunosuppressive regimen was 383.8 ± 27.2 mg 
of cyclosporine and 13.8 ± 0.8 mg of prednisone; in 
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addition, 23.5% were taking sulfasalazine, and 5.9% 
were using diphenoxylate hydrochloride with atro-
pine sulfate (Lomotil). 
In the symptomatic group, in response to the 
question, "overall, since your liver transplant, are 
the symptoms of your ulcerative colitis better, 
worse or the same?", 82.4% indicated improve-
ment, none reported a worsening, and 17.6% indi-
cated no change (P < 0.001 compared to pre-
OLTx). Of the three patients reporting no change, 
however, two reported that the overall severity of 
colitis symptoms continued to be moderate follow-
ing OLTx and one reported a shift from severe to 
moderate overall colitis severity. 
A separate question was asked about overall 
symptom severity. During the year prior to trans-
plant, the overall severity of colitis symptoms was 
rated as having been severe by 35.3%, moderate by 
52.9%, and mild by 11.8% of these patients. In 
contrast, at follow-up, 88.2% patients reported im-
provement, with 52.9% reporting no colitis symp-
toms, 29.4% mild symptoms, 17.6% moderate 
symptoms, and none indicating severe colitis symp-
toms (P < 0.001, pre- versus post-OLTx, mild 
versus moderate plus severe symptom categories 
combined). 
The frequencies of various ulcerative colitis 
symptoms before and after transplantation are 
shown in Table I. The percentages of patients who 
indicated improvement in symptom severity or 
frequency were calculated and tested using the 
binomial test; the results are summarized in Table 
2. In assessing improvement, all stated levels of 
severity or frequency were used, and a shift from 
a more severe to a less severe category was 
considered to be improvement. Further, those 
patients reporting no abnormality prior to OL Tx 
(eg, 1 to 2) bowel movements per day or a fre-
quency of "never") were not considered to be "at 
risk" for improvement and thus were not included 
in the denominator for these calculations. As may 
be seen in Table 2, compared to the year prior to 
OLTx, there was significant improvement at time 
of follow-up in overall colitis symptom severity. 
and the frequency of occurrence of daily bowel 
movements, crampy abdominal pain, bowel ur-
gency, the presence of pus or mucus in the stool, 
and the occurrence of flares. There was no signif-
icant improvement in either rectal pain or rectal 
bleeding. Among the eight patients experiencing a 
flare, the mean interval between OL Tx and the 
first flare was 37.0 ± 9.1 weeks; the earliest flare 
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TABLE 1. FREQUENCY OF ULCERATIVE COLITIS SYMPTOMS IN 
17 SYMPTOMATIC PATIENTS BEFORE AND AFTER 
TRANSPLANTATION 
Symptom Frequency 
Daily bowel movements 
(P < 0.001)* lowat 
highb 
Crampy abdominal pain 
(P < 0.01) lowe 
highd 
Bowel urgency 
(P < 0.01) lowe 
highd 
Pus or mucus in stool 
(P < 0.002) lowe 
highd 
Rectal bleeding lowe 
highd 
Rectal pain lowe 
highd 
Percent of 
patients 
Before After 
11.8 88.2 
88.2 1\.8 
23.5 82.4 
76.5 17.6 
5.9 64.7 
94.1 35.3 
47.1 94.1 
52.9 5.9 
70.6 100 
29.4 
58.8 94.1 
41.2 5.9 
*Test of differences in proportions before and after transplanta-
tion. 
ta = 1-2 bowel movements per day; b = three or more bowel 
movements per day; c = occurrence several days a month or 
less; d = occurrence several times a week or more. 
reported occurred at 12 weeks, while one patient 
indicated the first flare to have occurred as late as 
85 weeks. Nine patients reported that colonos-
copy (N = 7) or barium enema (N = 2) had been 
performed during the follow-up period (No patient 
reported the occurrence of colon surgery follow-
ing transplantation.) The histological appearance 
in 16 of the 17 patients with symptomatic colitis 
TABLE 2. ULCERATIVE COLITIS SYMPTOM IMPROVEMENT IN 17 
PATIENTS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION 
Number Number 
with with Significance 
symptom improvement level* (P) 
Overall symptom severity 17 15 <0.001 
(88.2%) 
Daily bowel movements 15 15 <0.001 
(100.0%) 
Crampy abdominal pain 16 [4 <0.001 
(87.5%) 
Rectal pain \3 8 NS 
(61.5%) 
Bowel urgency [6 12 <0.01 
(75.0%) 
Pus or mucus in stool 14 12 <O.OO[ 
(85.7%) 
Recta[ bleeding 15 10 NS 
(66.7%) 
Flares requiring treatment 11 9 <0.006 
(8\.8%) 
*Binomia[ test, one-tailed. NS = not statistically significant. 
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TABLE 3. NUMBER OF DAYS UNABLE TO FUNCTION 
NORMALLY IN DAILY ACTIVITIES BECAUSE OF ULCERATIVE 
COLITIS SYMPTOMS OR COMPLICATIONS-RESPONSES OF 17 
SYMPTOMATIC PATIENTS 
None 
1-2 per month 
3-4 per month 
>6 but <30 per month 
Nearly every day 
Pre-OLTx 
3 (17.6%) 
4 (23.5%) 
2 (11.9%) 
4 (23.5%) 
4 (23.5%) 
Post-OLTx 
8 (47.0%) 
7 (41.2%) 
2 (11.8%) 
o 
o 
during the follow-up period revealed mild colitis in 
six (46%), moderate colitis in six (47%), and 
severe colitis in three (18%). This distribution in 
terms of disease severity graded histologically did 
not differ significantly from that observed prior to 
transplantation_ 
Two aspects of quality of life were assessed: the 
first involved the impact of ulcerative colitis symp-
toms on the ability to function normally in daily 
activities, and the second assessed the overall 
impact of liver transplantation with immunosup-
pression as estimated by changes in the ability to 
work or carry out normal activities_ As may be 
seen in Table 3, the impact of ulcerative colitis 
symptomatology on the ability to function nor-
mally was substantially less, but not eliminated, 
during the follow-up period. Of the 17 with symp-
tomatic disease, 11 patients reported improvement 
and six reported no change; of these six, three 
reported that there had been no days during which 
their ulcerative colitis symptoms had prevented 
them from functioning normally during the year 
prior to transplant. Thus, there was overall im-
provement in II of the 14 patients (78.6%) who 
had been unable to function normally at least once 
a month pretransplant (P < 0.006). None of these 
patients had been able to function normally, as 
measured by the ability to work or participate in 
usual activities, at time of transplantation because 
of the severity of their liver disease. Thus, the 
responses to the question "which category best 
describes your present activity'?" primarily reflect 
the effect of transplantation, which reversed the 
end-stage liver disease. As may be seen in Table 4, 
altogether 13 of the 17 patients reported an im-
provement in their overall ability to pursue normal 
activities following liver transplantation (P < 
0.006). This finding suggests that ability to work or 
feeling well enough to work following transplanta-
tion may have reflected factors other than ulcer-
ative colitis disease activity per se. 
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TABLE 4. OVERALL ABILITY TO FUNCTION FOLLOWING LIVER 
TRANSPLANTATION-RESPONSES OF 17 SYMPTOMATIC 
PATIENTS 
9 (52.9%) 
1 (5.9%) 
3 (17.6%) 
3 (17.6%) 
1 (5.9%) 
Working full time 
Working part time 
Well enough to work but are not working for 
other reasons 
Not able to work but able to care for themselves 
at home 
Requiring intermittent hospitalization unrelated 
to ulcerative colitis 
DISCUSSION 
The results of this study using a survey question-
naire suggest that ulcerative colitis disease activity 
as subjectively characterized by each patient signif-
icantly improves in the short run (31-175 weeks) 
following liver transplantation for end-stage liver 
disease. This improvement following transplanta-
tion could be ascribed to the transplant, the use of 
cyclosporine and prednisone, the changes in life-
style or emotional support, or the mandatory period 
of rest. With respect to the possible role of immu-
nosuppression, it is to be noted that short-term 
cyclosporine administration to small groups (N = 
1-6 patients) with ulcerative colitis or erohn's 
disease has been reported to improve symptoms in 
the majority of such patients (20-22). Similarly, 
corticosteroids also have been used successfully to 
treat ulcerative colitis. Thus it should be noted that 
in the current study, the steroid portion of the 
immunosuppression regimen was 10.8 ± 0.5 mg/day 
of prednisone among the six asymptomatic patients 
and 13.8 ± 0.8 mg/day among the 17 patients who 
had been symptomatic prior to transplantation. In 
addition, psychological factors also may playa role 
in perceived improvement. The reversal of end-
stage liver disease, resulting in a lessened inward 
focus on status of physical being and an increased 
interest in or more hopeful attitude toward outward 
activities that have come within reach as a result of 
the liver disease having been "cured," may be a 
reason for the observed improvement (23-25). 
The findings of this study also raise questions about 
the perception of ulcerative colitis symptoms and 
their severity. Specifically, prior to transplantation, 
the study group could be divided into two groups: 
those with and those without ulcerative colitis symp-
toms. The first unanswered question arises from the 
fact that both of these groups were comprised of 
individuals with comparable colonoscopy-docu-
mented pancolitis. The second unanswered question 
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arises from the information provided by the 17 pa-
tients who had had symptomatically active ulcerative 
colitis prior to transplant: Why is it that during the 
follow-up period, 17.6% of these patients reported no 
change in response to the question "are the symp-
toms of your ulcerative colitis better, worse, or the 
same," when at the same time they indicated the 
overall severity of their colitis to have decreased at 
the time of follow-up? Such discrepancies emphasize 
the problem of deciphering the interrelationships of 
perceived improvement, recall of symptomatology, 
and relative changes either in actual disease activity 
or symptom severity. Specific answers to the ques-
tions and issues raised are beyond the scope of the 
current study. Future studies, which may include 
such objective measures as colonoscopy findings or 
adsorption/absorption assessment of topical versus 
humoral delivery of cyclosporine or new immunosup-
pressive drugs such as FK506, may provide useful 
information. Neuropsychological assessments might 
also increase our understanding. Finally, however, it 
will be interesting to determine how long the currently 
reported survey questionnaire findings of ulcerative 
colitis symptom severity improvement will continue. 
APPENDIX: QUESTIONNAIRE USED TO 
OBTAIN INFORMATION FROM PATIENTS 
CONCERNING ULCERATIVE COLITIS 
SYMPTOMS 
1. Overall, since your liver transplant, are the 
symptoms of your colitis better, worse, or 
about the same? (circle one) 
2. Compare the severity of your colitis symptoms 
during the year before you had your liver trans-
plant and now (during the last three months). 
Use the code shown below. 
The year before transplant__ Now __ 
o = no colitis symptoms 
1 = mild colitis symptoms 
2 = moderate colitis symptoms 
3 = severe colitis symptoms 
3. On the average, how many bowel movements 
were/are you having per day? Use the code 
shown below. 
The year before transplant __ Now __ 
A = 1-2 per day 
B = 3-5 per day 
C = 6 or more per day 
4. On average, how often do/did you experience 
crampy abdominal pain in the time periods 
specified? Use the code shown below. 
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The year before transplant__ Now __ 
0= never 
1 = several times per month 
2 = several times per week 
3 = just about every day 
5. On average, how often do/did you have rectal 
pain in the time periods specified? Use the code 
shown below. 
The year before transplant __ Now __ 
o = never 
1 = several times per month 
2 = several times per week 
3 = just about every day 
6. On average, how often do/did you have a sense 
of bowel urgency during the time periods indi-
cated? Use the code shown below. 
The year before transplant __ Now __ 
o = never 
t = several times per month 
2 = several times per week 
3 = just about every day 
7. On average, how often do/did you experience 
pus or mucous in your stool during the time 
periods specified? Use the code shown below. 
The year before transplant __ Now __ 
o = never 
1 = several times per month 
2 = several times per week 
3 = just about every day 
8. On average, how often do/did you have bleed-
ing from your rectum during the time periods 
specified? Use the code shown below. 
The year before transplant__ Now __ 
0= never 
1 = several times per month 
2 = several times per week 
3 = just about every day 
9. On average, how many flares of your colitis 
requiring treatment in the hospital did you have 
during the year before your transplant and 
during the entire time since your transplant and 
now. (Put the number of flares on the corre-
sponding line). 
The year before transplant __ 
The time after transplant __ 
to. On average, how many flares of your colitis did 
you have that required you to see your doctor 
as an outpatient during the year before your 
transplant and during the entire time since your 
transplant and now. (Put the number of flares 
on the corresponding line). 
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The year before transplant __ 
The time after transplant __ 
II. On average, how many days per month were 
you unable to function completely normally in 
your daily activities because of ulcerative coli-
tis or its complications during the year before 
your transplant and during the last 3 months? 
Use the code shown below. 
The year before transplant__ Now __ 
A = 1-2 days per month 
B = 3-4 days per month 
C = 4-6 days per month 
D = more than 6 but not every day 
E = nearly every day 
12. Which description best describes your present 
activity? (Circle the correct answer) 
I. working full-time 
2. working less than 20 hours per week 
3. not able to work but caring for self at 
home 
4. requiring hospitalization intermittently 
5. requiring hospitalization constantly 
6. feel well enough to work but not working 
for other reasons 
13. If your colitis became active after your liver 
transplant, what was the length of time between 
your transplant and the onset of your colitis 
activity? (Please record the answer in weeks) 
14. For each time period below, what was your 
dose (number of tablets per day) of Azulfidine 
(sulfasalazine )? 
The year before transplant__ Now __ 
IS. For each time period below, what was your 
dose (in milligrams per day) of prednisone? 
The year before transplant__ Now __ 
16. For each time period below, what was your 
dose (number of tablets per day) of Lomotil or 
Imodium? 
The year before transplant__ Now __ 
17. For each time period below, what was your 
dose (number of tablets per day) of Imuran 
(azathioprine)? 
The year before transplant __ Now __ 
18. For each of the time periods below, put a check 
mark if you used steroid enemas at any time 
(for example, Proctofoam, Cortenema). 
The year before transplant__ Now (the last 
three months) __ 
19. List all of the medications you are currently 
taking. You should also include in the list, all 
over-the-counter medications such as aspirin, 
tylenol, metamucil, vitamins, etc. (please print). 
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For each medication provide: 
Name ____________________________ __ 
Tablet strength __________ _ 
No. of tablets/dose ________ _ 
No. of doses/day _________ _ 
20. Have you had any surgery on your colon since 
your transplant? 
Yes No I don't know (circle one) 
20a. If yes, what was/were the reasons? 
__ cancer in my colon 
__ abnormal colon biopsies but not can-
cer (dysplasia) 
__ severe colon symptoms that could 
not be cured by medications 
__ large, distended colon with abdomi-
nal pain (toxic megacolon) 
__ severe hemorrhage 
__ perforation (hole) in the colon 
stricture of the colon 
__ for treatment of complications of 
ulcerative colitis not directly related 
to the colon (extraintestinal compli-
cations) 
__ I don't know 
__ other reasons (explain) ________ _ 
20b. If yes, what were the approximate dates of 
surgery? 
21. Have you developed: 
21 a. Cancer of the colon? 
Yes No I don't know (circle one) 
21 b. Dysplasia of the colon? 
Yes No I don't know (circle one) 
22. Have you had a colonoscopy since your trans-
plant? Yes No 
If yes, what was the approximate date? 
What was the reason? 
What were the results (if known)? 
23. Have you had a barium enema since your 
transplant? Yes No 
If yes, what were the dates? __ 
What was the reason? 
What were the results (if known)? 
24. When you were originally diagnosed as having 
ulcerative colitis how much of your colon was 
involved? 
___ my entire colon 
__ just the left colon 
___ rectum and sigmoid colon 
___ just the rectum 
__ don't know 
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25. Which description best characterized the initial 
onset of your colitis? (Check one) 
__ I. Mild-less than four bowel movements 
a day; no fever, weight loss or anemia. 
__ 2. Moderate-4-5 bowel movements a 
day; loose usually with blood, some-
times with crampy abdominal pain re-
lieved by passing the bowels; occasion-
ally fatigue or lowered appetite and 
weight loss and sometimes the presence 
offever 
__ 3. Severe-more than six stools per day; 
usually large amounts of constant liquid 
stool, with loss of weight, low blood 
count (anemia), considerable bleeding 
from the colon, fever, extreme fatigue, 
weakness and prostration 
25a. If the course of your colitis, since it first 
started, has been one consisting of periods 
of worsening alternating with periods of 
quiescence (minimal or no symptoms), 
were most of your attacks mild, moderate, 
or severe? 
26. Which description best describes the course of 
your colitis since initial onset? (Check one) 
_ 1. Intermittent attack of symptoms with 
complete resolution between attacks 
2. No further attacks since initial attack 
__ 3. Mostly continuous symptoms without 
remission 
27. When did you learn you had ulcerative colitis? 
Years:__ or Age: __ 
28. Since your transplant, has your doctor detected 
blood in your stool? (circle one) 
Yes No I don't know 
29. What new medical problems, if any, have 
arisen since your transplant? 
Thank you very much for completing the ques-
tionnaire. The space below is for you to give 
any additional information that you think would 
be helpful and for further explanation of any of 
your answers above. 
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